Vitamin D and bone health status in beta thalassemia patients-systematic review.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a systematic review.

The aim of this systematic review was to estimate the prevalence of vitamin D deficiency in thalassemia, as well as its association with osteoporosis/low bone mass.

Why It Was Studied

Thalassemia is a chronic congenital disease characterized by a combination of endocrine and metabolic disorders.

Bone disease is a very common complication related to the poor absorption of calcium, the secondary chronic renal disease with low vitamin D, as well as multiple endocrine risk factors.

Who the Included Studies Covered

The methodological quality of the included studies was assessed with the validated Newcastle-Ottawa Quality Assessment Scale adapted for cross-sectional studies and cohort studies respectfully and the Cochrane Collaboration for clinical trials.

What Was Measured

Bone disease is a very common complication related to the poor absorption of calcium, the secondary chronic renal disease with low vitamin D, as well as multiple endocrine risk factors.

The subject headings attached to it are Bone Density, Cross-Sectional Studies, Health Status, Vitamin D, Vitamin D Deficiency, Vitamins and beta-Thalassemia.

Author keywords: Beta thalassemia, Bone health, Osteoporosis and Systematic review.

What This Means in Plain Language

This is a systematic review of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2021 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.